# Peptide binding, presentation and immune recognition

Source: https://onco.cc/terms/binding-presentation-recognition/  
OnCo record `binding-presentation-recognition` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A peptide can bind a display molecule, be displayed by a cell, or be recognized by an immune receptor. These are different questions that require different evidence.

## Summary

Binding prediction estimates one part of antigen selection. Immunopeptidomics examines peptides recovered with HLA molecules, while immune assays investigate receptor binding and functional responses. A primary melanoma study directly identified naturally presented mutated peptides and separately tested their immunogenicity. A consortium study likewise evaluated prediction against measured immune interactions. A candidate supported at one stage should retain that evidence level rather than being described as a demonstrated therapeutic target.

## Fields

- Kind: Term
- Last checked: 2026-11-09

## Notes

- Peptide-to-HLA binding and TCR-to-peptide-HLA binding are different contacts. Evidence maps to claims: a binding prediction supports a model estimate for one exact peptide and allele (Reynisson et al., 2020, PMID 32406916); measured binding supports binding under that assay; immunopeptidomics supports association with the recovered preparation (Purcell et al., 2019, PMID 31092913), not guaranteed cancer-cell origin, surface location or complete recovery; peptide-HLA multimer staining shows cells binding a defined reagent (Altman et al., 1996, PMID 8810254), not affinity or killing; only a controlled response to naturally presenting target cells supports recognition or the measured function. Supplied-peptide stimulation can bypass processing, and secretion and target-cell death are different outputs.

## Sources

- Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.: https://doi.org/10.1038/ncomms13404
- Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.: https://doi.org/10.1016/j.cell.2020.09.015
- NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data.: https://doi.org/10.4049/jimmunol.1700893
- Primary evidence for the antigen-presentation teaching distinctions: https://doi.org/10.1093/nar/gkaa379
- Primary evidence for the antigen-presentation teaching distinctions: https://doi.org/10.1038/s41596-019-0133-y
- Primary evidence for the antigen-presentation teaching distinctions: https://doi.org/10.1126/science.274.5284.94

## Connected records

- terms: [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Immune-cell cytotoxicity assays](https://onco.cc/terms/immune-cytotoxicity-assays/), [Immunogenicity and clinical efficacy](https://onco.cc/terms/immunogenicity-versus-efficacy/), [Immunopeptidome](https://onco.cc/terms/immunopeptidome/), [Immunopeptidomics](https://onco.cc/terms/immunopeptidomics/), [Multi-epitope constructs and antigen processing](https://onco.cc/terms/multi-epitope-constructs/), [Neoantigen](https://onco.cc/terms/neoantigen/), [Peptide-HLA binding and ligand prediction](https://onco.cc/terms/peptide-hla-binding-prediction/), [Peptide-HLA multimer staining](https://onco.cc/terms/peptide-hla-multimer-staining/), [Self-similarity and immune-recognition specificity](https://onco.cc/terms/self-similarity-immune-recognition/)
- pathways: [Antigen presentation & immune editing](https://onco.cc/pathways/antigen-presentation-immunoediting/)

---
JSON: https://onco.cc/api/v1/entities/binding-presentation-recognition.json